These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 7513437

  • 1. [New prospective therapy for benign prostatic hyperplasia with finasteride].
    Miano L, Manieri C, Paradiso Galatioto G, Vicentini C.
    Riv Eur Sci Med Farmacol; 1993; 15(2):111-9. PubMed ID: 7513437
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study].
    Andersen JT, Wolf H, Ekman P, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K.
    Ugeskr Laeger; 1996 Sep 02; 158(36):5030-5. PubMed ID: 8928243
    [Abstract] [Full Text] [Related]

  • 4. Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study.
    Lukkarinen O, Lehtonen T, Talja M, Lundstedt S, Tiitinen J, Taari K.
    Ann Chir Gynaecol; 1999 Sep 02; 88(4):299-303. PubMed ID: 10661828
    [Abstract] [Full Text] [Related]

  • 5. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E.
    Arch Intern Med; 1994 Jan 10; 154(1):83-8. PubMed ID: 7505563
    [Abstract] [Full Text] [Related]

  • 6. [Treatment of benign prostatic hyperplasia with finasteride. Results after 7 years of follow-up].
    Martínez Sarmiento M, Cuñat Albert E, López Alcina E, Pontones Moreno JL, Sanz Chinesta S, Jiménez Cruz JF.
    Actas Urol Esp; 1997 Feb 10; 21(2):105-10. PubMed ID: 9214205
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study].
    Tveter KJ, Beisland HO, Andersen JT, Wolf H, Ekman P, Johansson JE, Kontturi M, Lehtonen T.
    Tidsskr Nor Laegeforen; 1996 Nov 10; 116(27):3226-30. PubMed ID: 9011975
    [Abstract] [Full Text] [Related]

  • 8. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
    Yoshida O, Oishi K, Okada Y, Mizutani Y, Itokawa Y, Tomoyoshi T, Okada K, Komatz Y, Matsuda T, Takeuchi H.
    Hinyokika Kiyo; 1996 Apr 10; 42(4):323-31. PubMed ID: 8693970
    [Abstract] [Full Text] [Related]

  • 9. 5alpha-reductase inhibitors/finasteride.
    Stoner E.
    Prostate Suppl; 1996 Apr 10; 6():82-7. PubMed ID: 8630236
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK, Kashem MA, Shameem IA, Kibria SA.
    Bangladesh Med Res Counc Bull; 2005 Aug 10; 31(2):54-61. PubMed ID: 16967810
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.
    Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, Elhilali MM.
    CMAJ; 1996 Nov 01; 155(9):1251-9. PubMed ID: 8911291
    [Abstract] [Full Text] [Related]

  • 12. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
    Magoha GA.
    East Afr Med J; 1998 May 01; 75(5):260-3. PubMed ID: 9746993
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological treatment of benign prostatic hyperplasia with finasteride: a clinical review.
    Ekman P.
    Arch Esp Urol; 1994 Nov 01; 47(9):883-7; discussion 887-8. PubMed ID: 7530944
    [Abstract] [Full Text] [Related]

  • 14. Finasteride in the treatment of benign prostatic hyperplasia.
    Ekman P, Andersen JT, Wolf H.
    Acta Urol Belg; 1996 Mar 01; 64(1):IX-XII. PubMed ID: 8659328
    [Abstract] [Full Text] [Related]

  • 15. [Finasteride in the treatment of benign prostatic hypertrophy].
    Ekman P.
    J Urol (Paris); 1993 Mar 01; 99(6):299-302. PubMed ID: 7516372
    [Abstract] [Full Text] [Related]

  • 16. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
    Granados Loarca EA.
    Arch Esp Urol; 1999 Apr 01; 52(3):201-8. PubMed ID: 10371735
    [Abstract] [Full Text] [Related]

  • 17. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
    Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J, Proscar Long-Term Efficacy and Safety Study Group.
    J Urol; 2004 Mar 01; 171(3):1194-8. PubMed ID: 14767299
    [Abstract] [Full Text] [Related]

  • 18. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H, Lan O, Poulain JE, Comenducci A.
    Prog Urol; 2005 Dec 01; 15(6):1090-5. PubMed ID: 16429658
    [Abstract] [Full Text] [Related]

  • 19. [Finasteride (Proscar) for benign prostatic hypertrophy].
    Matzkin H, Chen J, Braf Z.
    Harefuah; 1993 Dec 15; 125(12):453-6, 496. PubMed ID: 7509305
    [Abstract] [Full Text] [Related]

  • 20. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group.
    J Androl; 1991 Dec 15; 12(6):372-5. PubMed ID: 1722792
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.